^(131)I与抗甲状腺药物治疗Graves甲亢的疗效评价  

Curative Effect Evaluation of ^(131)I and ATD Therapy for Patients with Graves' Hyperthyroidism

作　　者：刘艳[1] 付立武[2] 魏月芳[1] 常永超[1] 黄诚[1] 

机构地区：[1]河南科技大学第一附属医院,河南洛阳471003 [2]洛阳市中心医院,河南洛阳471003

出　　处：《河南科技大学学报（医学版）》2008年第4期265-266,共2页Journal of Henan University of Science & Technology:Medical Science

摘　　要：目的评价131I与抗甲状腺药物(ATD)治疗Graves甲亢的疗效。方法将240例甲亢患者随机分为2组,分别用131I和ATD治疗,治疗后随访2年。结果131I治疗Graves甲亢的疗效优于ATD;发生突眼方面两者之间的差异无统计学意义;131I治疗后甲减的发生率高于ATD;Graves甲亢治愈后复发明显低于ATD治疗,出现甲亢性心脏病、血像、肝功能受损等方面低于ATD。结论131I治疗Graves甲亢疗效明显优于ATD治疗。Objective To evaluate the treatment of Graves＇ hyperthyroidism with tat I and ATD. Methods 240 clinical patients with Graves＇ hyperthyroidism were collected. They were divided into 2 groups treated with ATD and ^131I to compare the total curative effects. All patients were followed up for 2 years. Results The curative effect of ^131I was better than that of ATD ; the incidence of Graves＇ ophthalmopathy of the two groups was not significantly different. The Graves＇ hyperthyroidism patients treated with ^131I got the more incidence rate of hypothyroidism. The patients cured with ^131I had the less Graves＇ hyperthyroidism relapse than in those with ATD. In the patients treated with ^131I,the incidence of hyperth liver function damage, leukopenia and so on was less than in those treated with ATD. therapy excels the ATD in the treatment of the patients with Graves＇ hyperthyroidism.

关 键 词：^131I GRAVES甲亢 甲状腺功能减退 突眼 

分 类 号：R581.1[医药卫生—内分泌]